Synergistic Inhibition of Human Immunodeficiency Virus Type 1 in vitro by 6-0-butanoylcastanospermine (MDL 28574) in Combination with Inhibitors of the Virus-Encoded Reverse Transcriptase and Proteinase
| Autor: | Mohinder S. Kang, A. S. Tyms, Debra L. Taylor, C. G. Bridges, T. M. Brennan |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
0301 basic medicine
Nevirapine 030106 microbiology General Medicine Biology Drug interaction 01 natural sciences Virology Virus Reverse transcriptase 0104 chemical sciences 010404 medicinal & biomolecular chemistry 03 medical and health sciences Zidovudine Zalcitabine medicine Didanosine Saquinavir medicine.drug |
| Zdroj: | Antiviral Chemistry and Chemotherapy. 6:143-152 |
| ISSN: | 2040-2066 |
| Popis: | The anti-human immunodeficiency virus type 1 (HIV-1) activity of the α-glucosidase 1 inhibitor 6-0-butanoylcastanospermine (MDL 28574) was assessed in combination with the 2′,3′-dideoxynucleoside analogues zidovudine (AZT), didanosine (ddl) and zalcitabine (ddC). MDL 28574 was also evaluated in combination with the non-nucleoside reverse transcriptase (RT) inhibitor nevirapine and the HIV proteinase inhibitor saquinavir (Ro-31-8959). Drug interactions were examined by the isobologram technique and by calculating combination indices (C.l.s). In all cases synergistic inhibition of HIV-1 replication was observed. In three-drug combinations, a marked synergistic antiviral effect was also observed, with C.I. values in the range 0.35-0.44 for MDL 28574 in combination with AZT and nevirapine, and in the range 0.34-0.67 for MDL 28574 in combination with AZT and saquinavir. Moreover, the combination of MDL 28574 with other drugs did not produce detrimental effects on cell division. MDL 28574 is currently in clinical trials and may have an important role in combination chemotherapy for HIV infections. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|